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Nordisk Inc, Princeton, NJ, USA
OBJECTIVES: To estimate clinical and economic outcomes 5
years after initiating add-on insulin detemir (IDet) or neutral pro-
tamine Hagedorn insulin (NPH) therapy among type 2 diabetes
patients taking metformin ± glimepiride. METHODS: Baseline
characteristics and treatment effect data were taken from a mul-
ticenter, 26-week, randomized controlled trial among insulin
naïve type 2 subjects (mean HbA1c: 8.56%; age: 60.8 years).
Reductions in HbA1c were similar, though statistically signiﬁ-
cant improvements in body weight (1.6kg difference; p < 0.001)
and reduction of intra-day variation of fasting plasma glucose (p
< 0.008) favoring IDet were observed. Additionally, risk of all
hypoglycemia with IDet was 47% lower (p < 0.001), and risk of
nocturnal hypoglycemia was 55% lower (p < 0.001). A pub-
lished and validated computer simulation model of type 2 dia-
betes was used to project differences in quality-adjusted life
expectancy (QALE) and direct medical costs (pharmacy plus
complication costs) over a 5 year time horizon. Costs were taken
from published sources in the US. Clinical outcomes and costs
were discounted at 3% annually. Sensitivity analyses were per-
formed. RESULTS: Initiation of IDet therapy was projected to
improve QALE by 0.17 ± 0.09 QALYs versus NPH after 5 years.
Treatment with IDet was associated with slight reductions in the
relative risk for major diabetes-related comorbidities. Direct
medical costs were higher in the IDet treatment group than in
the NPH group, leading to an ICER of $25,368 per QALY
gained. Acceptability curve analysis indicated that there was a
94% probability of IDet being cost-effective versus NPH with a
willingness to pay threshold of $50,000 per QALY gained. The
results were most sensitive to variation in hypoglycemic event
rates. CONCLUSION: Among insulin-naïve type 2 patients, ini-
tiation of IDet was estimated to improve quality-adjusted life
expectancy and would be considered good value for money by
commonly accepted standards in comparison to NPH.
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ECONOMIC BURDEN OF DIABETES ATTRIBUTABLE TO
OVERWEIGHT AND OBESITY AMONG U.S. ADULTS
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OBJECTIVES: To estimate the direct medical care expenditures
of diabetes attributable to overweight and obesity. METHODS:
Cross-sectional analyses were performed with 25,346 adults
from the 2002 Medical Expenditure Panel Survey (MEPS). Dia-
betic patients were identiﬁed if they reported having diabetes in
the medical conditions ﬁle of MEPS. Diabetic patients were clas-
siﬁed as normal weight (body mass index (BMI) ≥18.5 to <25),
overweight (BMI 25 to <30), or obese (BMI ≥ 30) based on their
BMI. Medical costs of diabetes were estimated using a two-part
model with adjustment for study variables such as age, gender,
BMI, etc. Medical costs of diabetes attributable to overweight or
obesity were respectively estimated by the prevalence of diabetes
and the incremental medical costs in people with and without
diabetes. Data were analyzed using SAS and SUDAAN statisti-
cal softwares to adjust for the complex sample design. RESULT:
The age-adjusted prevalence of diabetes in the US was 6.5%
(13.4 million(M) people) representing 3.4% (2.5M) in normal-
weight, 5.4% (4.3M) in overweight, and 12.5% (6.6M) in
obesity group. Among diabetic patients, 6.1 million diabetic
cases were associated with overweight or obese groups: 1.7M
(40%) in the overweight and 4.1M (61%) in the obesity group.
These extra diabetic cases resulted in $32.5 billion(B) direct
medical costs of diabetes attributable to overweight ($9.1B) and
obese ($23.4B). Diabetic men are more prevalent than women
(2.3M vs. 1.9M) in overweight, resulting in cost attributable to
overweight/obese of $5.7B vs. $3.4B. However, in obese group,
diabetic women were more prevalent (3.4M vs. 3.2M with costs
of $14.3B vs. $9.4B). CONCLUSIONS: Overweight and obesity
are strongly associated with a rising prevalence of diabetes and
an increased economic burden among people with diabetes. Ini-
tiation of aggressive intervention is recommended to increase
patient awareness of importance in controlling their excess
weights which cause extra economic burden of diabetes.
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IMPROVING THE MEASUREMENT OF THE COST OF
DIABETES-RELATED COMPLICATIONS: RESULTS FROM A
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Previous studies have shown that diabetes is a costly chronic con-
dition due mainly to the treatment of complications that occur
with increasing frequency and severity as the disease progresses.
However, results vary greatly primarily because they rely on dif-
ferent modeling techniques, secondary data sources and/or on
numerous assumptions to project potential long-term costs.
OBJECTIVES: To estimate the short-term and long-term health
care costs of diabetes and diabetes-related complications for a
large cohort of patients followed prospectively. METHODS: All
prevalent cases of diabetes in Ontario from 1992 to 2002 were
followed for up to 10 years, until death, or out migration. This
Ontario Diabetes Database was linked to various health care
administrative datasets to develop comprehensive costing of dia-
betes and related complications. Seven diabetes-related compli-
cations were tracked over time (ischemic heart disease,
myocardial infarction (MI), heart failure, stroke, amputation,
renal failure, and blindness). Costs were compiled for outpatient
services, prescription drugs, long-term care, homecare and hos-
pital services for each year of follow-up. RESULTS: Of the
734,113 diabetics in the database, there were over 1.26 million
non-fatal cardiovascular-related events during the 10-year time
period. The average ﬁrst year cost of amputation was $34,469
and $4,721 in subsequent years and renal failure was $22,116
in the ﬁrst year and $10,033 in subsequent years. CONCLU-
SIONS: This study reports the results of a regression analysis on
a large database to obtain estimates of the health care costs asso-
ciated with diabetes-related complications. Costs are not simply
the health care costs of complications; instead they reﬂect the
increase in all health care costs in the year in which complica-
tions occur as well as in subsequent years. Accurate measure-
ment of the short- and long-term health care costs associated
with diabetes-related complications is necessary to help identify
possible areas for priority setting in health care decision-making
and research.
